Portfolio company
SHIFTBIO
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This deep-tech company develops a programmable natural nanoparticle drug delivery platform for pharmaceutical and biotechnology partners to enable targeted therapeutic applications.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
ParcelBio
This deep-tech firm develops mRNA delivery technologies and programmable medicines for biotechnology and pharmaceutical organisations to treat autoimmune diseases and oncology.
Granza Bio
This deep-tech company develops attack particle medicines to treat patients with cancer, autoimmune diseases and infections.
GenEdit
This deep-tech firm develops polymer nanoparticle delivery systems for genetic medicines to treat autoimmune diseases for the pharmaceutical and biotechnology industries.
Kodikaz Therapeutic Solutions
This deep-tech company develops a non-viral delivery platform for cell-specific gene therapies to treat cancer patients.
A-Alpha Bio
This deep-tech company provides protein interaction data and predictive models to pharmaceutical firms for the discovery and engineering of new medicines.
Hone Bio
This company develops lipid nanoparticle targeting technology for pharmaceutical and biotechnology firms to enable precise drug delivery beyond the liver.
Nanograb
This company develops an artificial intelligence platform to design targeted gene delivery vectors and nanoparticles for pharmaceutical organisations developing genetic medicines.
PROSION
This deep-tech company develops small molecule inhibitors to target undruggable proteins for patients with cancer and other serious diseases.
